百利天恒:伦康依隆妥单抗两项III期临床完成首例入组

财中社
Jul 23

7月23日,百利天恒(688506)发布公告,公司自主研发的全球首创EGFR×HER3双抗ADC伦康依隆妥单抗/宜泽康(BL-B01D1/iza-bren)两项III期临床试验于近日分别完成首例受试者入组,涉及适应症为经内分泌治疗失败的晚期HR+HER2-乳腺癌和含铂化疗失败的局部晚期或转移性胆道癌。  BL-B01D1是全球首个且唯一获批上市的EGFR×HER3双抗ADC,截至目前已在中国和美国...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10